AR044399A1 - Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen - Google Patents
Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienenInfo
- Publication number
- AR044399A1 AR044399A1 ARP040101732A ARP040101732A AR044399A1 AR 044399 A1 AR044399 A1 AR 044399A1 AR P040101732 A ARP040101732 A AR P040101732A AR P040101732 A ARP040101732 A AR P040101732A AR 044399 A1 AR044399 A1 AR 044399A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydrogen
- aralkyl
- bond
- optionally substituted
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
Abstract
La presente proporciona agentes farmacológicos que se unen a receptores activados por el proliferador de peroxisoma (PPARs). Por consiguiente, los compuestos de la presente son útiles para el tratamiento de condiciones mediadas por la actividad del receptor de PPAR en mamíferos. Dichas condiciones incluyen dislipidemia, hiperlipidemia, hipercolesteremia, aterosclerosis, hipertrigliceridemia, falla cardiaca, infarto al miocardio, enfermedades vasculares, enfermedades cardiovasculares, hipertensión, obesidad, inflamación, artritis, cáncer, enfermedad de Alzheimer, trastornos de la piel, enfermedades respiratorias, trastornos oftálmicos, enfermedades inflamatorias del intestino, colitis ulcerativa, enfermedad de Crohn, y condiciones en donde están implicadas la tolerancia dañada a glucosa, hiperglicemia y resistencia a insulina, tal como diabetes de tipo 1 y de tipo 2, y síndrome X. Reivindicación 1: Un compuesto de la fórmula (1), en donde L es un radical seleccionado del grupo que consiste en las fórmula (2) y (3), en donde: R1 es hidrógeno, alquilo opcionalmente sustituido, arilo, heteroarilo, aralquilo o cicloalquilo; R2 es hidrógeno, hidroxi, oxo, alquilo opcionalmente sustituido, arilo, aralquilo, alcoxi, ariloxi, aralcoxi, alquiltio, ariltio o aralquiltio; R3 es hidrógeno; o R2 y R3 combinados son alquileno que en conjunto con los átomos de carbono a los cuales están unidos forman un anillo de 5 a 7 miembros fusionados; o R2 y R3 combinados son un enlace entre los átomos de carbono a los cuales están unidos; n es 0 o un entero de 1 ó 2; Ya es hidrógeno; o Ya y R2 combinados son un enlace entre los átomos de carbono a los cuales están unidos; R4a es hidrógeno; o R4a e Ya combinados son un enlace entre los átomos de carbono a los cuales están unidos; R'' es hidrógeno, alquilo opcionalmente sustituido, alcoxi o halógeno; m es un entero de 1 ó 2; Yb es hidrógeno; R4b es hidrógeno; o R4b y Yb combinados son un enlace entre los átomos de carbono a los cuales están unidos; R y R' son independientemente hidrógeno, halógeno, alquilo opcionalmente sustituido, alcoxi, aralquilo o heteroaralquilo; o R y R' combinados junto con los átomos de carbono a los cuales están unidos forman un anillo aromático o heteroaromático de 5 ó 6 miembros fusionado, opcionalmente sustituido, siempre que R y R' estén unidos a los átomos de carbono adyacentes entre sí; o R-C y R'-C independientemente pueden ser reemplazados por nitrógeno; X1 es -Z-(CH2)p-Q-W, en donde; Z es un enlace, O, S, S(O) o S(O)2; o Z es -C(O)NR5-, en donde R5 es hidrógeno, alquilo o aralquilo; p es un entero de 1 a 8; Q es un enlace; o Q es O(CH2)r- o -S(CH2)r-, en donde r es 0 o un entero de 1 a 8; o Q es -C(OH2)1-8O-, -S(CH2)1-8O-, -S(CH2)1-8S- o -C(O)-, o Q es -C(O)NR6-, en donde R6 es hidrógeno, alquilo opcionalmente sustituido, cicloalquilo, arilo, heteroarilo, aralquilo o heteroaralquilo; o Q es -NR7, -NR7C(O)-, -NR7C(O)NR8- o - NR7C(O)O-, en donde R7 es hidrógeno, alquilo opcionalmente sustituido, cicloalquilo, arilo, heteroarilo, aralquilo o heteroaralquilo; R8 es hidrógeno, alquilo o aralquilo; W es cicloalquilo, arilo, heterociclilo, aralquilo o heteroaralquilo; o W y R6 tomados con el átomo de nitrógeno al cual están unidos forman un anillo bicíclico de 8 a 12 miembros, el cual puede estar opcionalmente sustituido o puede contener otro átomo heterogéneo seleccionado de oxígeno, nitrógeno y azufre; X2 es C(R9)2-, O, S o -NR10-, en donde R9 es hidrógeno o alquilo inferior; R10 es hidrógeno, alquilo o aralquilo; siempre que W no sea 2-metilquinolin-4-ilo cuando Z es O, p es 1, Q es un enlace, X2 es -C(R9)2-, en donde R9 es hidrógeno, y X1 está localizado en la posición 4; o W no es 2-butil-4-cloro-5-hidroximetilimidazol-1-ilo cuando Z es un enlace, p es 1, Q es un enlace, X2 es -NR10- en donde R10 es hidrógeno, y X1 está ubicado en la posición 4; o un isómero óptico del mismo; o una mezcla de isómeros ópticos de los mismos o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47206703P | 2003-05-20 | 2003-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044399A1 true AR044399A1 (es) | 2005-09-14 |
Family
ID=33476920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101732A AR044399A1 (es) | 2003-05-20 | 2004-05-19 | Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7652061B2 (es) |
| EP (1) | EP1638963B1 (es) |
| JP (1) | JP4637843B2 (es) |
| KR (2) | KR100849747B1 (es) |
| CN (1) | CN1795193B (es) |
| AR (1) | AR044399A1 (es) |
| AT (1) | ATE442365T1 (es) |
| AU (1) | AU2004240754B9 (es) |
| BR (1) | BRPI0410779A (es) |
| CA (1) | CA2525764C (es) |
| CL (1) | CL2004001169A1 (es) |
| CO (1) | CO5650248A2 (es) |
| DE (1) | DE602004023080D1 (es) |
| EC (1) | ECSP056175A (es) |
| ES (1) | ES2331131T3 (es) |
| IS (1) | IS8160A (es) |
| MA (1) | MA27777A1 (es) |
| MX (1) | MXPA05012465A (es) |
| NO (1) | NO20056056L (es) |
| PE (1) | PE20050157A1 (es) |
| PT (1) | PT1638963E (es) |
| RU (1) | RU2374241C2 (es) |
| TN (1) | TNSN05295A1 (es) |
| TW (1) | TW200524918A (es) |
| WO (1) | WO2004103995A1 (es) |
| ZA (1) | ZA200508905B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2531279A1 (en) * | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
| NZ551603A (en) | 2004-06-24 | 2010-11-26 | Incyte Corp | N-substituted piperidines and their use as pharmaceuticals |
| KR20070024639A (ko) * | 2004-06-24 | 2007-03-02 | 인사이트 산 디에고 인코포레이티드 | 아미도 화합물 및 약제로서의 이의 용도 |
| PE20060594A1 (es) * | 2004-09-09 | 2006-08-18 | Novartis Ag | Composicion farmaceutica que contiene un agonista de ppar |
| CN102036662B (zh) * | 2005-06-27 | 2013-02-27 | 新树股份有限公司 | 利用肉豆蔻衣木脂素预防和治疗ppar介导的疾病的方法 |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| ES2589736T3 (es) | 2006-03-31 | 2016-11-16 | Novartis Ag | Derivados de piridina como inhibidores de DGAT |
| PE20080888A1 (es) | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
| JP5401544B2 (ja) | 2008-07-15 | 2014-01-29 | ノバルティス アーゲー | Ｄｇａｔ１阻害剤としてのヘテロアリール誘導体 |
| JP5062097B2 (ja) * | 2008-08-21 | 2012-10-31 | 富士通株式会社 | 情報処理装置、情報処理装置の制御方法、および情報処理装置の制御プログラム |
| US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| PT2781516T (pt) | 2010-10-07 | 2017-03-15 | Novartis Ag | Novas formas cristalinas do sal de sódio do ácido (4-{4-[5-(6-trifluorometil-piridin-3-ilamino)-piridin-2-il]-fenil}-ciclo-hexil)-acético |
| MX2013008192A (es) | 2011-01-13 | 2013-12-16 | Novartis Ag | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. |
| MY162413A (en) | 2011-01-13 | 2017-06-15 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
| CN103619862A (zh) | 2011-04-14 | 2014-03-05 | 诺瓦提斯公司 | 糖苷衍生物及其用途 |
| US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| EP2729454B1 (en) | 2011-07-08 | 2015-09-16 | Novartis AG | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| WO2013043744A2 (en) | 2011-09-21 | 2013-03-28 | Inception 1, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
| EP2766358B1 (en) | 2011-10-13 | 2016-06-22 | Novartis AG | Novel oxazine derivatives and their use in the treatment of disease |
| JP5966014B2 (ja) | 2011-11-28 | 2016-08-10 | ノバルティス アーゲー | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MA37439B1 (fr) | 2012-04-27 | 2017-02-28 | Novartis Ag | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). |
| US9108956B2 (en) | 2012-04-27 | 2015-08-18 | Novartis Ag | Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors |
| JP6466924B2 (ja) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| DK3119397T3 (da) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3437651A1 (en) | 2017-08-03 | 2019-02-06 | Université de Strasbourg | Peptides for treatment and prevention of nonalcoholic fatty liver disease |
| EP3723782A1 (en) | 2017-12-14 | 2020-10-21 | Université de Strasbourg | Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis |
| JP2022507958A (ja) | 2018-11-27 | 2022-01-18 | ノバルティス アーゲー | 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物 |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽 |
| EP3897697B1 (en) | 2018-12-21 | 2023-03-29 | Université de Strasbourg | Peptides for treatment and prevention of diabetes and associated disorders |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| WO2023152698A1 (en) | 2022-02-10 | 2023-08-17 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5045540A (en) * | 1990-05-25 | 1991-09-03 | Warner-Lambert Co. | Amino acid derivatives with angiotensin II antagonist properties |
| PT915088E (pt) * | 1997-10-31 | 2003-01-31 | Hoffmann La Roche | Derivados de d-prolina |
| CA2366264A1 (en) * | 1999-04-02 | 2000-10-12 | Bristol-Myers Squibb Company | Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase |
| GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
-
2004
- 2004-05-19 RU RU2005139525/04A patent/RU2374241C2/ru not_active IP Right Cessation
- 2004-05-19 AR ARP040101732A patent/AR044399A1/es not_active Application Discontinuation
- 2004-05-19 WO PCT/EP2004/005434 patent/WO2004103995A1/en active Application Filing
- 2004-05-19 US US10/556,988 patent/US7652061B2/en not_active Expired - Fee Related
- 2004-05-19 DE DE602004023080T patent/DE602004023080D1/de not_active Expired - Lifetime
- 2004-05-19 AU AU2004240754A patent/AU2004240754B9/en not_active Ceased
- 2004-05-19 TW TW093114121A patent/TW200524918A/zh unknown
- 2004-05-19 MX MXPA05012465A patent/MXPA05012465A/es active IP Right Grant
- 2004-05-19 KR KR1020057022001A patent/KR100849747B1/ko not_active IP Right Cessation
- 2004-05-19 EP EP04739269A patent/EP1638963B1/en not_active Expired - Lifetime
- 2004-05-19 PE PE2004000511A patent/PE20050157A1/es not_active Application Discontinuation
- 2004-05-19 AT AT04739269T patent/ATE442365T1/de active
- 2004-05-19 PT PT04739269T patent/PT1638963E/pt unknown
- 2004-05-19 ES ES04739269T patent/ES2331131T3/es not_active Expired - Lifetime
- 2004-05-19 BR BRPI0410779-9A patent/BRPI0410779A/pt not_active IP Right Cessation
- 2004-05-19 JP JP2006529884A patent/JP4637843B2/ja not_active Expired - Fee Related
- 2004-05-19 CA CA2525764A patent/CA2525764C/en not_active Expired - Fee Related
- 2004-05-19 KR KR1020087000342A patent/KR100909918B1/ko not_active IP Right Cessation
- 2004-05-19 CN CN2004800140213A patent/CN1795193B/zh not_active Expired - Fee Related
- 2004-05-20 CL CL200401169A patent/CL2004001169A1/es unknown
-
2005
- 2005-11-03 ZA ZA200508905A patent/ZA200508905B/xx unknown
- 2005-11-15 MA MA28605A patent/MA27777A1/fr unknown
- 2005-11-18 EC EC2005006175A patent/ECSP056175A/es unknown
- 2005-11-18 TN TNP2005000295A patent/TNSN05295A1/en unknown
- 2005-11-30 IS IS8160A patent/IS8160A/is unknown
- 2005-12-15 CO CO05126527A patent/CO5650248A2/es not_active Application Discontinuation
- 2005-12-20 NO NO20056056A patent/NO20056056L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044399A1 (es) | Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen | |
| AR037655A1 (es) | Derivados de bencensulfonilo, una composicion farmaceutica que los comprende, el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento asociado al receptor retinoide x, un metodo para la preparacion de un agente alquilante | |
| US11547704B2 (en) | Chemical compounds | |
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| JP2019013227A5 (es) | ||
| US20210145771A1 (en) | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases | |
| AU2016250662A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| ECSP045368A (es) | "antagonistas de los receptores de trombina" | |
| AR050913A1 (es) | Compuestos derivados de tiazolpiridina como activadores de glucoquinasa; composiciones farmaceuticas que los contienen y su uso en medicamentos para el tratamiento de la diabetes tipo ii | |
| AR056548A1 (es) | Derivados de sulfonamidas, composiciones farmaceuticas y sus usos | |
| AR043355A1 (es) | Compuestos derivados de amida, preparacion de medicamentos que los contienen para el tratamiento y prevencion de trastornos asociados con glucocorticoides | |
| AR057869A1 (es) | Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto | |
| AU2017279027A1 (en) | Chemical Compounds | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AU2017292522A9 (en) | Combination comprising EP4 antagonist and immune checkpoint inhibitor | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| AR063123A1 (es) | Derivados biciclicos y triciclicos como antagonistas del receptor de trombina | |
| AR053415A1 (es) | Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion | |
| AR045856A1 (es) | Derivados de tropano sustituidos con imidazopiridinas,procedimiento de preparacion,composiciones farmaceuticas que los contienen y usos, | |
| KR20070014173A (ko) | Ｈｉｖ 인테그라제 억제제: 시클릭 피리미디논 화합물 | |
| AR041997A1 (es) | Derivados de oxaxol sustituidos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de la diabetes | |
| AR043875A1 (es) | Derivados de quinazolina, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR064831A1 (es) | Derivados de espiropiperidina-glicinamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |